Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study. Preliminary safety and efficacy data of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback